Over the past decade, revolutionary changes have taken place in the treatment of patients with EGFR mutation-positive NSCLC owing to the development of EGFR-TKIs, which are considered the first choice for the first-line treatment of this patient population. Here, EGFR is linked to non-small cell lung carcinoma.